Prediction of Chemoresistance—How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer
High-grade serous ovarian cancer (HGSOC) is one of the most lethal tumors generally and the most fatal cancer of the female genital tract. The approved standard therapy consists of surgical cytoreduction and platinum/taxane-based chemotherapy, and of targeted therapy in selected patients. The main t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/1/15 |
| _version_ | 1797344333162086400 |
|---|---|
| author | Jacek Wilczyński Edyta Paradowska Justyna Wilczyńska Miłosz Wilczyński |
| author_facet | Jacek Wilczyński Edyta Paradowska Justyna Wilczyńska Miłosz Wilczyński |
| author_sort | Jacek Wilczyński |
| collection | DOAJ |
| description | High-grade serous ovarian cancer (HGSOC) is one of the most lethal tumors generally and the most fatal cancer of the female genital tract. The approved standard therapy consists of surgical cytoreduction and platinum/taxane-based chemotherapy, and of targeted therapy in selected patients. The main therapeutic problem is chemoresistance of recurrent and metastatic HGSOC tumors which results in low survival in the group of FIGO III/IV. Therefore, the prediction and monitoring of chemoresistance seems to be of utmost importance for the improvement of HGSOC management. This type of cancer has genetic heterogeneity with several subtypes being characterized by diverse gene signatures and disturbed peculiar epigenetic regulation. HGSOC develops and metastasizes preferentially in the specific intraperitoneal environment composed mainly of fibroblasts, adipocytes, and immune cells. Different HGSOC subtypes could be sensitive to distinct sets of drugs. Moreover, primary, metastatic, and recurrent tumors are characterized by an individual biology, and thus diverse drug responsibility. Without a precise identification of the tumor and its microenvironment, effective treatment seems to be elusive. This paper reviews tumor-derived genomic, mutational, cellular, and epigenetic biomarkers of HGSOC drug resistance, as well as tumor microenvironment-derived biomarkers of chemoresistance, and discusses their possible use in the novel complex approach to ovarian cancer therapy and monitoring. |
| first_indexed | 2024-03-08T11:00:50Z |
| format | Article |
| id | doaj.art-2297ec30a1bf4e6a9b33f4bed95c60e7 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-08T11:00:50Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-2297ec30a1bf4e6a9b33f4bed95c60e72024-01-26T15:57:46ZengMDPI AGCurrent Oncology1198-00521718-77292023-12-0131122924910.3390/curroncol31010015Prediction of Chemoresistance—How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian CancerJacek Wilczyński0Edyta Paradowska1Justyna Wilczyńska2Miłosz Wilczyński3Department of Gynecological Surgery and Gynecological Oncology, Medical University of Lodz, 4 Kosciuszki Str., 90-419 Lodz, PolandLaboratory of Virology, Institute of Medical Biology of the Polish Academy of Sciences, 106 Lodowa Str., 93-232 Lodz, PolandDepartment of Tele-Radiotherapy, Mikolaj Kopernik Provincial Multi-Specialized Oncology and Traumatology Center, 62 Pabianicka Str., 93-513 Lodz, PolandDepartment of Gynecological, Endoscopic and Oncological Surgery, Polish Mother’s Health Center—Research Institute, 281/289 Rzgowska Str., 93-338 Lodz, PolandHigh-grade serous ovarian cancer (HGSOC) is one of the most lethal tumors generally and the most fatal cancer of the female genital tract. The approved standard therapy consists of surgical cytoreduction and platinum/taxane-based chemotherapy, and of targeted therapy in selected patients. The main therapeutic problem is chemoresistance of recurrent and metastatic HGSOC tumors which results in low survival in the group of FIGO III/IV. Therefore, the prediction and monitoring of chemoresistance seems to be of utmost importance for the improvement of HGSOC management. This type of cancer has genetic heterogeneity with several subtypes being characterized by diverse gene signatures and disturbed peculiar epigenetic regulation. HGSOC develops and metastasizes preferentially in the specific intraperitoneal environment composed mainly of fibroblasts, adipocytes, and immune cells. Different HGSOC subtypes could be sensitive to distinct sets of drugs. Moreover, primary, metastatic, and recurrent tumors are characterized by an individual biology, and thus diverse drug responsibility. Without a precise identification of the tumor and its microenvironment, effective treatment seems to be elusive. This paper reviews tumor-derived genomic, mutational, cellular, and epigenetic biomarkers of HGSOC drug resistance, as well as tumor microenvironment-derived biomarkers of chemoresistance, and discusses their possible use in the novel complex approach to ovarian cancer therapy and monitoring.https://www.mdpi.com/1718-7729/31/1/15ovarian cancerpredictionbiomarkerschemoresistance |
| spellingShingle | Jacek Wilczyński Edyta Paradowska Justyna Wilczyńska Miłosz Wilczyński Prediction of Chemoresistance—How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer Current Oncology ovarian cancer prediction biomarkers chemoresistance |
| title | Prediction of Chemoresistance—How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer |
| title_full | Prediction of Chemoresistance—How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer |
| title_fullStr | Prediction of Chemoresistance—How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer |
| title_full_unstemmed | Prediction of Chemoresistance—How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer |
| title_short | Prediction of Chemoresistance—How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer |
| title_sort | prediction of chemoresistance how preclinical data could help to modify therapeutic strategy in high grade serous ovarian cancer |
| topic | ovarian cancer prediction biomarkers chemoresistance |
| url | https://www.mdpi.com/1718-7729/31/1/15 |
| work_keys_str_mv | AT jacekwilczynski predictionofchemoresistancehowpreclinicaldatacouldhelptomodifytherapeuticstrategyinhighgradeserousovariancancer AT edytaparadowska predictionofchemoresistancehowpreclinicaldatacouldhelptomodifytherapeuticstrategyinhighgradeserousovariancancer AT justynawilczynska predictionofchemoresistancehowpreclinicaldatacouldhelptomodifytherapeuticstrategyinhighgradeserousovariancancer AT miłoszwilczynski predictionofchemoresistancehowpreclinicaldatacouldhelptomodifytherapeuticstrategyinhighgradeserousovariancancer |